ORLANDO, Fla., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Orlando-based health sciences company XYMOGEN reported more than $5.2 million in sales for January, a record for the company.
"That's $2 million more than in January 2012 and $1 million more than we've ever done in any one month," said Mike Mahoney, senior vice president at XYMOGEN. "We started off this month very, very big. ... We're averaging $237,301 a day in sales."
Mahoney says the month's sales exceeded projections of $4 million. October sales were $4.2 million.
"The vast majority of January's growth may be attributed to the success of our annual XYMOGEN XPERIENCE in January. It included a facility tour and a review of XYMOGEN's solid financial foundation, which is essential to funding growth initiatives moving forward," said Brian Blackburn, XYMOGEN's CEO and president. "More than 200 of our best customers descended on sunny Orlando for what proved to be the most successful and celebrated event in company history."
Doctors, pharmacists and other health care practitioners from across the United States, Canada and Puerto Rico visited XYMOGEN's new 136,000-square-foot manufacturing facility and headquarters, which opened in May. It includes more than 40,000 square feet of space dedicated to manufacturing and packaging and a 4,000-square-foot, full-service laboratory to test all raw materials and goods.
It's a significant factor in XYMOGEN's future growth. "We have the latest equipment, the latest capabilities, to optimize the manufacturing of our formulas," Blackburn said.
XYMOGEN is projecting $59 million in sales for 2013 and $75 million in 2014. The company reported $46.5 million in revenue last year and has experienced 36 consecutive quarters of growth.
"Even more impressive may be that in all but the fourth quarter of each year, revenues for each quarter have exceeded the prior quarter," Blackburn said.
Blackburn says XYMOGEN's growth in a sluggish economy is due to the company's "strong core values and equally strong financial footing."
"The average 11-year tenure of our 40-plus functional medicine consultants, coupled with the fact we make public our quarterly financial statements, assures our customers we are well-positioned to honor our long-term commitment to their interests and those of their patients," Blackburn said.
Mahoney agrees strong partnerships are key.
"It's relationships. It's people first," he said. "We want to listen to our customers and we always have. … We take the time to listen to what our representatives want. This is what makes us unique. That gives us the opportunity to release better products that are more welcome."
XYMOGEN produces probiotics, antioxidants and a host of health supplements. The products are sold directly to health care providers and not available retail.
And with the new facility, XYMOGEN is able to create custom formulas and packaging for its customers.
That's a significant benefit, Mahoney says, and another factor that makes XYMOGEN attractive in the functional medicine market. XYMOGEN is also introducing additional medical foods in 2013 under the PharmaceutX brand and expanding its fast-growing BioenergX line of nutrients.
XYMOGEN, a family-owned, health sciences company with headquarters in Orlando, Fla., has been providing high-quality dietary supplements to licensed health care practitioners for more than a quarter century.
The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.
XYMOGEN's strength as a company was reinforced in 2007, 2008, 2010, 2011 and 2012 when it was recognized by Inc. Magazine as one of the 5,000 fastest-growing private companies in America.
The company's 136,000-square-foot manufacturing facility is also GMP (good manufacturing practices) and GMP for Sport registered by NSF International.
CONTACT: Sara R. Brady 407-702-6632 Distributed by Sara Brady Public Relations, Inc. 222 W. Comstock Avenue, Suite 215 Winter Park, Florida 32789 www.sarabradypr.comSource: XYMOGEN